Briacell Therapeutics Corp., of Berkeley, Calif., said it upsized and closed its nonbrokered private placement of 12.09 million common shares at CA7 cents per common share for gross proceeds of CA$846,300 (US$644,152). The proceeds will be used to fund research and development, for the repayment of outstanding unsecured convertible notes and for general working capital and general corporate purposes.
Biontech SE, of Mainz, Germany, has filed to raise up to $100 million in an IPO. That follows the company's $325 million series B round completed in July. It currently has seven product candidates undergoing eight clinical trials, but it is gearing up to take at least four more programs into the clinic over the next 12 months, including its first CAR T therapy for solid tumors, a small-molecule Toll-like receptor 7 agonist, an RNA molecule encoding an antibody drug (Ribomab) and an RNA molecule encoding a cytokine (Ribocytokine). The company plans to list on Nasdaq under the symbol BNTX. (See BioWorld, July 10, 2019.)
Insilico Medicine, of Hong Kong, said it completed a $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, Bold Capital Partners and other investors, including series A investors. The funding will be used to commercialize its validated generative chemistry and target identification technology. The company said it has identified promising targets in a variety of therapeutic areas, including cancer, fibrosis and immunology.
Pharvaris BV, of Leiden, the Netherlands, which is focused on the discovery and development of oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, said it completed a $66 million series B financing, led by Foresite Capital together with Bain Capital Life Sciences, Venbio Partners and Venrock Partners, as well as existing investors LSP, Kurma Partners and Idinvest Partners. The proceeds will support the clinical development of an oral therapy to treat HAE, designated PHA-121. The first subjects have been dosed in a phase I trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PHA-121 in healthy subjects. A multiple ascending-dose study is anticipated to start early next year.
Sernova Corp., of London, Ontario, said it completed a nonbrokered private placement of CA$4.685 million (US$3.564 million), and issued a total of 23.43 million units priced at CA20 cents each. Net proceeds will be used to support funding of the company's clinical programs, including its FDA-cleared U.S. phase I/II regenerative medicine trial and to advance internal preclinical development programs and corporate/academic collaborations utilizing the company's platform technologies to treat diabetes, hemophilia and other serious disease conditions.
Trucode Gene Repair Inc., of San Francisco, said it has emerged from stealth mode and raised $34 million from investors, including Kleiner Perkins and GV (formerly known as Google Ventures). The company has established an intellectual property estate for its triplex gene editing technology to correct mutations that cause sickle cell disease, cystic fibrosis and other genetic disorders. The technology employs proprietary synthetic peptide nucleic acid oligomers and DNA correction sequences to edit disease-causing mutations by harnessing natural DNA repair mechanisms. The mechanism of editing does not cause double-stranded breaks seen with CRISPR and other nuclease-based editing technologies and has the potential for intravenous delivery without viral vectors.
Xeris Pharmaceuticals Inc., a Chicago-based specialty pharma firm, said it entered an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increases the borrowing base from $45 million to up to $85 million, subject to certain conditions, and extends the maturity date of the debt to as late as June 2024, if the second tranche is drawn.